3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Neoplasms
7
Carcinoma, Hepatocellular
7
Neoplasm Metastasis
5
Carcinoma, Non-Small-Cell Lung
5
Recurrence
4
Prostatic Neoplasms
4
Breast Neoplasms
4
Melanoma
3
Lymphoma, B-Cell, Marginal Zone
3
Lymphoma
3
Head and Neck Neoplasms
3
Sarcoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Polycystic Ovary Syndrome
2
Pleural Effusion, Malignant
2
Mesothelioma, Malignant
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Anxiety Disorders
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neuroblastoma
1
Nephrotic Syndrome
1
Neoplasms, Plasma Cell
1
NSCLC
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Interventions
Amifostine
19
Cisplatin
15
Radiotherapy
13
Etoposide
10
Cyclophosphamide
9
Carboplatin
8
Paclitaxel
7
Filgrastim
7
Drug Therapy
5
Cytarabine
5
apatinib
4
sodium thiosulfate
3
Methylprednisolone
3
Methotrexate
3
Gemcitabine
3
Docetaxel
3
sargramostim
2
pegfilgrastim
2
etoposide phosphate
2
camrelizumab
2
Vincristine
2
Pyridoxine
2
Peripheral Blood Stem Cell Transplantation
2
Nivolumab
2
Mitoxantrone
2
Melphalan
2
Irinotecan
2
Ifosfamide
2
Fibroblast Growth Factor 7
2
Epoetin Alfa
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Drug-Related Side Effects and Adverse Reactions
×
Pharmaceutical Preparations
×
Clear all
NCT04138381
2023-03-27
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2
Unknown
30 enrolled